Immunochemical and clinical effects of immunosuppressive treatment in monoclonal IgM neuropathy.
AUTOR(ES)
Ernerudh, J H
RESUMO
A pathogenic role of the M protein in monoclonal IgM neuropathy has been suggested. This is based among other things on a close relation between immunosuppressive treatment, lowered concentration of M protein, and clinical effect. We studied five patients with monoclonal IgM and antibodies to peripheral nerve myelin. The immunosuppressive treatment was beneficial in three of the patients. In three patients there was a relationship between antibody concentration and clinical effect (in one there was no change in antibody concentrations and correspondingly no change in clinical status, and in two patients clinical improvement corresponded to decreased antibody concentrations). In two patients, however, there was no clear correlation, since one patient improved despite increasing antibody concentrations and one patient did not improve despite a lowered antibody concentration. It is therefore possible that other mechanisms may contribute to the effect of treatment.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=1015195Documentos Relacionados
- IgM monoclonal gammopathy and neuropathy in two siblings.
- Increase in albumin, IgG, and IgM blood-nerve barrier indices in human diabetic neuropathy.
- IgG monoclonal paraproteinaemia and peripheral neuropathy.
- Peripheral neuropathy associated with monoclonal IgM anti-Pr2 cold agglutinins.
- Frequency of central lesions in polyneuropathy associated with IgM monoclonal gammopathy: an MRI, neurophysiological and immunochemical study.